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Glutamine synthetase is a ubiquitous central enzyme in nitrogen metabolism that is con-
trolled by up to four regulatory mechanisms, including adenylylation of some or all of the
twelve subunits by adenylyl transferase. It is considered a potential therapeutic target for the
treatment of tuberculosis, being essential for the growth of Mycobacterium tuberculosis, and
is found extracellularly only in the pathogenic Mycobacterium strains. Human glutamine syn-
thetase is not regulated by the adenylylation mechanism, so the adenylylated form of bacte-
rial glutamine synthetase is of particular interest. Previously published reports show that,
when M. tuberculosis glutamine synthetase is expressed in Escherichia coli, the E. coli ade-
nylyl transferase does not optimally adenylylate the M. tuberculosis glutamine synthetase.
Here, we demonstrate the production of soluble adenylylated M. tuberulosis glutamine syn-
thetase in E. coli by the co-expression of M. tuberculosis glutamine synthetase and M. tuber-
culosis adenylyl transferase. The differential inhibition of adenylylated M. tuberulosis
glutamine synthetase and deadenylylated M. tuberulosis glutamine synthetase by ATP
based scaffold inhibitors are reported. Compounds selected on the basis of their enzyme
inhibition were also shown to inhibit M. tuberculosis in the BACTEC 460TB™ assay as well
as the intracellular inhibition of M. tuberculosis in a mouse bone-marrow derived macro-
phage assay.
Introduction
Tuberculosis (TB) is a worldwide pandemic, caused by infection with the bacterium Mycobac-
terium tuberculosis. Although current treatment can be effective, existing drugs must be taken
for at least six months to prevent relapse. Poor treatment compliance contributes directly to
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the emergence of multidrug- and extensively drug-resistant (MDR and XDR) strains of M.
tuberculosis. New targets for drugs are therefore required. These new drugs should also sim-
plify and shorten the treatment period, as well as reduce drug-drug interactions in patients co-
infected with HIV. Drug discovery programmes for infectious diseases are normally focussed
on pathogen proteins whose function is known to be essential to the bacterial cell, combined
with a lack of mammalian homologues. One such potential drug target for TB is adenylylated
glutamine synthetase (GS).
GS (EC 6.3.1.2) catalyzes the reversible conversion of L-glutamic acid, ATP and ammonia
to L-glutamine, ADP and inorganic phosphate via a γ-glutamyl phosphate intermediate [1]. It
is a central enzyme in nitrogen metabolism, and can be regulated by at least four different
mechanisms: (a) adenylylation and deadenylylation of a conserved tyrosine residue, (b) con-
version between a relaxed (inactive) and taut (active) state depending on the divalent metal
cation present, (c) cumulative feedback inhibition by multiple end products of glutamine
metabolism, and (d) repression and derepression of GS biosynthesis in response to nitrogen
availability [1].
Three distinct forms of GS occur, with GS-I found only in bacteria (eubacteria) and archaea
(archaebacteria) [2]. GS-II occurs only in eukaryotes, and soil-dwelling bacteria, while GS-III
genes have been found only in a few bacterial species. Two significant prokaryotic GS-I sub-
divisions exist: GS-Iα and GS-Iβ [3]. The GS-Iβ enzyme is regulated via the adenylylation/
deadenylylation cascade, which does not occur in the GS-Iα or GS-II sub-divisions. M. tuber-
culosis and Escherichia coli GS are regulated in this manner, while the human homologue
belongs to GS-II and is not subject to adenylylation, a difference that can be exploited by devel-
oping drugs that are only active against the adenylylated form of the enzyme.
The extent of adenylylation of the E. coli GS is regulated in response to the intracellular con-
centrations of 2-ketoglutarate and glutamine, via the reversible adenylylation of a tyrosine resi-
due (Tyr397) in each subunit of GS [1, 4–8]. The presence of adenylylated GS predominates in
a nitrogen-rich, carbon-limited media, while the deadenylylated form tends to predominate
under conditions of nitrogen limitation [1, 4–15]. The regulation of the adenylylation state of
GS is accomplished by three proteins: (1) uridylyltransferase/uridylyl-removing enzyme, (2)
the signal transduction protein PII, and (3) adenylyltransferase or ATase. High intracellular
concentrations of glutamine activate the uridylyl-removing enzyme, which causes the deuridy-
lylation of PII. This interacts with the ATase, which then catalyses the adenylylation of the GS.
A high intracellular 2-ketoglutarate concentration activates uridylyltransferase, which transfers
UMP to each subunit of PII, forming PII-UMP. The PII-UMP interacts with the Atase, which
in turn catalyses the removal of AMP from the GS. Research on the effect of glucose, ammonia
and glutamic acid concentrations has shown that the adenylylation state of GS is a function of
metabolic flux rather than absolute concentration only [10]. The activity of GS is therefore reg-
ulated by both the nature and the availability of the ammonia source [1,8]. The current view is
that the level of GS activity is inversely related to the degree of adenylylation [reviewed in 1, 9,
10] and that adenylylated residues may be present on any number of subunits from zero to 12,
depending on carbon and nitrogen availability [13, 16–21]. GS is therefore responsible for the
assimilation of ammonia when the available ammonia in the environment is restricted, as well
as for the formation of glutamine for the synthesis of protein and other nitrogen compounds.
In ammonia-rich medium, the level of GS is low and GS functions primarily for the synthesis
of glutamine.
A number of factors make GS a potential drug target in the fight against TB, including
being considered essential for the survival of M. tuberculosis [22–25]. The GS inhibitor L-
methionine-S,R-sulphoximine (MSO) inhibits growth of M. tuberculosis both in vitro and in
vivo [22,23]. It is located extracellularly, a characteristic that is found only in the pathogenic
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mycobacteria such as M. tuberculosis and Mycobacterium bovis, and not with the non-patho-
genic strains of Mycobacterium smegmatis and Mycobacterium phlei [21,22]. This location
means a potential drug does not have to pass the M. tuberculosis cell wall barrier. It appears to
play an important role in cell wall biosynthesis, in the form of a cell wall component found
only in pathogenic mycobacteria: poly-L-glutamate/glutamine [26, 27].
M. tuberculosis GS (MtbGS) has previously been successfully expressed in heterologous sys-
tems including the non-pathogenic mycobacterial strain M. smegmatis and E. coli [28–30].
Mehta et al expressed M. tuberculosis GS in E. coli host strains that were deficient in either
chromosomal GS, or both chromosomal GS and ATase [30]. They found that the E. coli ATase
was inefficient in adenylylating the heterologous M. tuberculosis GS, with only ~25% of sub-
units being modified. A lack of E. coli ATase yielded completely deadenylylated M. tuberculosis
GS. As a result no crystal structure exists for M. tuberculosis fully adenylylated GS [31]. A num-
ber of studies have been undertaken targeting MtbGS as a potential therapeutic target however,
in none of these investigations was an attempt made to exploit the dichotomy between adeny-
lylated and deadenylylated GS [32–39]. As outlined prokaryotic GS is regulated via a complex
cascade that is based on the availability of NH4
+ and glucose to the organism and the intracel-
lular concentrations of 2-ketoglutarate and glutamine [1, 4–8]. This regulation results in the
adenylylation or deadenylylation of the GS with a concomitant switch in the enzymes affinity
from Mn2+ to Mg2+[1, 4–8, 30]. The adenylylation and the switch in metal ion specificity sig-
nificantly impacts on the enzyme activity of GS and therefore probably impacts on the struc-
ture of the active site. It is proposed that this dichotomy may be exploitable in creating GS
inhibitors that target only prokaryotic GS as only bacterial GS have regulation via the adenyly-
lation/deadenylylation cascade.
Here, we describe the production of both the deadenylylated and adenylylated forms of
MtbGS in E. coli. Deadenylylated MtbGS is produced by constitutive expression of MtbGS in
an E. coli strain deficient in both E. coli GS and ATase activities, while adenylylated MtbGS is
produced when co-expressed with an inducible M. tuberculosis ATase. Adenylylation was mea-
sured using the γ-glutamyl transferase assay, mass spectrometry and determination of phos-
phate content. IC50 values of the known GS inhibitors MSO and phosphinotricin (PhosT)
were also determined. A battery of ATP scaffold compounds were identified and screened for
their differential inhibitory effect on adenylylated MtbGS and deadeylylated MtbGS. Two of
these compounds showed micromolar activity against MtbGS, acceptable activity against a
cell-free and macrophage model of M. tuberculosis indicating their possible druggability. The
two compounds identified here represent a good starting point for a hit-to-lead campaign to
develop selective, druggable agents capable of selectively inhibiting the adenylated form of
MtbGS in view of identifying novel agents against M. tuberculosis infection.
Experimental procedures
Plasmids and bacterial strains
E. coli JM109 (Promega Corporation) was used for cloning. Restriction endonucleases were
purchased from Fermentas Life Sciences and Ex TaqTM DNA polymerase from TaKaRa Bio
Inc.
M. tuberculosis glutamine synthetase glnA gene was PCR amplified from genomic DNA of
M. tuberculosis H37Rv (ATCC 25618) using the oligonucleotide primers TB1: 5’-GATGGATCC
ACCCGATAACCAG-3’and TB2: 5’-GATGGATCCTCGAAAAACCTCG-3’. The amplified
DNA was then digested with BamHI (sites underlined in primer sequences) and ligated with
similarly digested pBluescript SKII+, generating plasmid pTBSK, with the glnA gene under con-
tol of the constitutive T3 promoter.
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The M. tuberculosis H37Rv adenylyl transferase glnE gene was PCR amplified from genomic
DNA using the oligonucleotide primers TBglnE-8: 5’-TAGCATATGGTCGTGACCAAAC-3’
and TBglnE-9: 5’-CAGGATCCTTAACTCCCGAACAC-3’. The amplified DNA was then co-
digested with NdeI and BamHI (sites underlined in primer sequence) and ligated with NdeI
and BglII digested pCDFDuet-1 (Novagen) to construct pTBGlnE, with glnE downstream of
the IPTG-inducible T7lac promoter.
For MtbGS expression, the chromosomal adenylyl transferase glnE gene of the glutamine
synthetase auxotroph YMC11 was deleted using the Quick and Easy E. coli Gene Deletion Kit
(Gene Bridges, GmbH) to create the strain YMC11E [40]. The Novagen λDE3 Lysogenization
Kit was used to create YMC11E(DE3).
Production of adenylylated and deadenylylated MtbGS
Deadenylylated MtbGS was expressed in YMC11E containing pTBSK. This strain was inoc-
ulated in 50 ml M9ZB medium (1% w/v N-Z-Amine A; 85 mM NaCl) containing M9 Salts
(22 mM Na2HPO4; 22 mM KH2PO4; 18 mM NH4Cl; 8.5 mM NaCl) and supplemented with
100 μg.ml-1 ampicillin, 1mM MgSO4 and 4% (w/v) glucose. The inoculum was grown at
28˚C for 16 hours with shaking at 220 rpm. Subsequently, 5 ml of the culture was trans-
ferred to 250 ml of the same medium, which was grown at 28˚C for 16 hours. The cultures
were harvested by centrifugation for 10 min at 16,300g (4˚C) and the bacterial pellet used
for MtbGS purification.
Adenylylated MtbGS was produced using YMC11E(DE3) containing both pTBSK and
pTBglnE. This strain was inoculated into 50 ml of the same medium as above, including 50 μg.
ml-1 streptomycin. The cultures were incubated at 33˚C for 16 hours with shaking at 220 rpm.
Thereafter, 5 ml was transferred to 250 ml of the same medium and grown at 33˚C for a fur-
ther 8 hours. M. tuberculosis adenylyl transferase expression was then induced by the addition
1 mM IPTG. After a further incubation at 33˚C for 16 hours with shaking at 220 rpm, the cul-
tures were harvested by centrifugation for 10 min at 16,300g (4˚C) and the bacterial pellet used
for MtbGS purification.
Purification of adenylylated and deadenylylated MtbGS
The purification of adenylylated and deadenylylated MtbGS from a cell free extract was carried
out in a three stage process; a streptomycin sulphate precipitation to remove contaminating
nucleic acid, an anion-exchange chromatography stage which removed the major fraction of
contaminating proteins and an AMP-Sepharose affinity chromatography”polishing” stage
which produced the purified enzyme (See Supporting Information for detail, S1 File).
Production and purification of adenylylated and deadenylylated E. coli
GS
For comparison purposes, adenylylated and deadenylylated E. coli GS was also heterologously
expressed and purified. Recombinant deadenylylated E. coli GS was produced in an E. coli
strain lacking chromosomal glnA (GS) and glnE (ATase) genes. Adenylylated E. coli GS was
produced in a strain lacking chromosomal glnA (GS) and glnD (uridilyl transferase) genes (See
Supplementary Information for detail, S1 File) [41, 42]. Sodium dodecyl-sulphate polyacryl-
amide gel electrophoresis (SDS-PAGE) was used to analyse the molecular mass and purity of
the isolated enzymes [43]. Protein concentrations were determined by using the Quant-ITTM
Protein Assay Kit (Invitrogen, USA) used in conjunction with the QUBITTM fluorometer.
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Determination of degree of adenylylation of purified GS
Mass spectrometry. A 40 μl aliquot of purified GS in 10 mM imidazole pH 7.0 was loaded
on an OPTI-LYNX C4 trap cartridge at 100 μl/min using 2% ACN (Acetonitrile)/0.1% FA
(Formic Acid). Samples were eluted using linear acetonitrile gradient (2–90% ACN/5% FA) in
5min and TOF-MS spectra, in the range 700–1700 mz, collected using QSTRA-Elite mass
spectrometer with TurboIon source installed. The multiply charged series of TBGS was decon-
voluted by the Bayesina Protein Recostruct tool of Bioanalyst QS 2.0 using a mass range of 40–
70kD and signal to noise threshold of 3.
Hydrolysis of GS for determination of phosphate content. The relative phosphate con-
tent of the purified GS proteins was determined by hydrolysis to release the phosphate [44].
Purified GS (4 to 8 nmol in 1 ml) was digested by the addition of 4 M HCl (1 ml), and the mix-
ture was evaporated to dryness. The residue was resuspended in 2 M HCl (1 ml) plus 20 μl of
H2O2 (30% v/v), and the mixture was again evaporated to dryness. Five sequential additions of
H2O2 (200 μl) with evaporation to dryness were used to complete the hydrolysis. The residue
was resuspended in Milli-Q water (1 ml), and phosphate content was determined by using the
BioVision Phosphate colorimetric assay kit as per supplier’s manual.
γ-Glutamyl transferase assay. The GS γ-glutamyl transferase enzyme activity was used to
calculate the degree of adenylylation of the purified GS using the standard method as outlined
by Shapiro and Stadtman [41].
Dose response assays: MtbGS inhibitor screening and specific activity determination.
Standard GS inhibitors methionine sulphoximine (MSO), phosphinotricin (PhosT) and a bat-
tery of 213 compounds were tested for inhibition of the adenylylated and dedenylylated forms
of MtbGS. Serial 4-fold dilutions of MSO and PhosT were prepared in DMSO. Two dilution
series were set up, one starting at 1 mM and the other at 2 mM. Eight dilutions were performed
in DMSO, to produce a concentration range of 1 mM– 61 nM or 2 mM—122 nM. Twenty μl
of each dilution was distributed into duplicate wells of the reaction plate. Each well received
164 μl MtbGS in 50 mM HEPES, 4 mM NH4Cl, 1.8 mM MnCl2 or MgCl2. For adenylylated
MtbGS, HEPES pH 6.95 and MnCl2 were used, while for deadenylylated MtbGS, HEPES pH
7.15 and MgCl2 were required. The plates were incubated at 37˚C for 2 hours, after which the
reactions were initiated by adding sodium glutamate and ATP to final concentrations of 4 mM
and 0.8 mM respectively, with a final reaction volume of 200 μl. After further 2 hour incuba-
tion, the reactions were terminated by the addition of 1 μl 50% trichloro acetic acid to each
well. Blank wells (no enzyme) were also prepared for each individual compound. In addition,
each plate contained control wells (10% DMSO without inhibitor) and blank control wells
(10% DMSO, no inhibitor, no enzyme). After termination of the reactions, ADP levels in each
well were determined by HPLC.
HPLC based enzyme assay. The enzyme activity of GS was determined by measuring the
ADP concentration by HPLC [45]. Samples were analysed on a Hewlett Packard series 1100
HPLC fitted with a Luna 5μm C18 column. Each sample was automatically injected (2 μl) and
separated with a mobile phase containing 51 mM KH2PO4, PIC A Low UV Reagent, 25% (v/v)
acetonitrile. An AMP, ADP and ATP standard was used to calibrate the HPLC and the con-
centration of ADP in each sample was determined by the area under the curve using Agilent
Technologies ChemStation software. The ADP values in the blank wells were subtracted from
enzyme-containing wells, and percentage enzyme activity in each well calculated relative to
the average net ADP values of the control wells without inhibitor. The enzyme activity was
expressed as a percentage of the maximum enzyme activity in the absence of any inhibitor.
HeLa cell cytotoxicity assay. HeLa cells (Human Negroid cervix epitheloid adenocarci-
noma, ECACC) were routinely maintained as monolayer cell cultures in Eagle’s minimal
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essential medium (EMEM) containing 5% fetal bovine serum, 2 mM L-glutamine and 50 μg/
ml gentamicin at 37˚C in a 5% CO2 incubator. To perform the cytotoxicity assay, the cells (3–
19 passages) were used to inoculate 96-well microtiter plates at plating densities of 7000 cells/
well. After incubating for 24 hours, the culture medium was replaced with medium containing
serial dilutions of the experimental compounds. Each dilution series consisted of 8 x 3-fold
serial dilutions, spanning the final concentration range 100–0.05 μM. Triplicate wells were
used for each concentration point (n = 3). The dilutions were prepared from compound stocks
of 10 mM in DMSO, thus the final DMSO content in the highest compound concentration
wells was 1%. Control wells consisted of cells incubated in medium with 1% DMSO, while
blank wells contained medium without cells. Emetine was used as a positive control drug stan-
dard. The plates were incubated for 48 hours after addition of the compounds. The cellular
protein present after the incubation period was fixed to the bottom of each well with cold 50%
TCA, washed in tap water and stained with 0.4% sulforhodamine B (SRB) in 1% acetic acid.
Unbound dye was removed by washing with 1% acetic acid, after which protein-bound dye
was solubilised with 10 mM Tris base and transferred to a duplicate 96-well plate. Optical den-
sity was measured at 540 nm using a Tecan Infinite F500 multiwell spectrophotometer. OD540
values of the blank wells were subtracted from the readings obtained for all the other wells, and
percentage cell viability at each test compound concentration calculated relative to the
untreated (DMSO alone) control wells. Percentage viability was plotted against Log (com-
pound concentration) and the IC50 for each compound calculated from fitted non-linear
regression dose-response curves using GraphPad Prism software.
Testing of compounds against M.tb strains in-vito and ex-vivo using the
BACTEC 460TB™ assay
Bacterial strains. All M.tb strains used were from a strain bank kept in the Division
Molecular Biology and Human Genetics of of Stellenbosch University. M.tb H37Rv reference
strain (ATCC 25618) and a clinical isolate of M.tb (Beijing220) were used to evaluate com-
pounds for anti-tuberculosis activity. The H37Rv strain was sensitive to the breakpoint con-
centrations (approximately 10x higher than their minimal inhibitory concentrations (MIC) of
isoniazid (0.25ug/ml), ethambutol (9.4ug/ml), and rifampicin (2.0ug/ml) [46]. However, the
Beijing220 clinical isolate was resistant to isoniazid and rifampicin [47, 48].
Test compounds. The compounds identified were used in the BACTEC 460TB™ assay
[49]. The identified compounds were dissolved and diluted with 100% DMSO.
Bacterial selection. All mycobacterial colonies were cultured and selected from Lowen-
stein-Jensen slant [50] cultures followed by culture in Middlebrook 7H9 mycobacterial growth
medium supplemented with OADC (0.005% v/v oleic acid (Merck), 0.5% w/v BSA Fraction V,
0.2% v/v glucose, 0.02% v/v catalase (Merck), w/v 0.085% NaCl). Cultures were stained by
acid-fast staining (Ziehl-Neelsen) to control for contamination.
BACTEC 460TB™ system determination of mycobacterial growth. The BACTEC
460TB™ system has been devised to monitor mycobacterial growth of the slow growing species.
The bacteria are grown on a radioactive substrate and the radioactive carbon dioxide produced
is directly proportional to the mycobacterial growth rate. Read-out values are expressed as
growth index (GI). M.tb reference strain H37Rv was cultured in 7H9 mycobacterial medium
(Difco) enriched with ADC (0.5% w/v BSA Fraction V, 0.2% v/v glucose, 0.015% v/v catalase
(Merck) with continuous stirring at 37˚C. When cultures reached a density of approximately
0.16 at OD600 (one McFarland), 0.1 ml was inoculated into a BACTEC 12B medium vial. These
primary cultures were incubated at 37˚C until a growth index of 500 (± 50) was reached. These
primary cultures were used for drug testing of known and unknown compounds. Compounds,
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resuspended in DMSO, were sterilized through a 13 mm organic solvent resistant syringe filter
with 0.22 micron pore size (Millex-LG). Undiluted and sequentially diluted samples were tested
for growth inhibitory activity. 0.1 ml of primary culture and 0.1 ml drug compound were added
to a BACTEC 460TB™ vial, the vials incubated at 37˚C, and the growth monitored every 24
hours. Controls included cultures with and without compound solvent. GI readings were con-
tinued until the controls reached the maximum GI value of or below 999. Control GI values
between 50 and 800 are normally used to evaluate the efficacy of compounds with possible anti-
tuberculosis activity.
Testing of screening hits against M.tb in a macrophage assay
M.tb cultures. M.tb clinical MDR strain (Beijing220) was cultured in 7H9 broth supple-
mented with 10% oleic acid-albumin-dextrose catalase (OADC, Difco, BD Biosciences, Moun-
tain View, CA, USA) and 2% glycerol and 0.05% Tween 80 (Glickman et. al., 2000). Liquid
cultures were grown for up to 3 weeks and stored at -80˚C in 1ml aliquots with 15% glycerol.
Clumps were eliminated by 30 passages through a needle (26-gauge 3/8; 0.45 x 10 for intrader-
mal injection; BD Biosciences, USA). Before infection, viability of mycobacteria was evaluated
by the propidium iodide exclusion method to ensure>90% viability. Contamination was
checked by the Ziehl-Neelsen stain. The required amount of mycobacteria was spun down at
16 300xg for 5 min. The supernatant was removed and the bacteria resuspended in PBS (phos-
phate buffered saline) and passaged again 20 times and then used for macrophage infection.
Manipulation of mouse bone marrow-derived macrophages (MBMM). This research
study was approved by the Stellenbosch University Animal Ethics committee on Animal Care
and Use and complies with the South African Animal Protection Act (Act no 71, 1962). Ani-
mal Ethics No. SU-ACUD14-00041. Mice were supplied by the Animal House of the Univer-
sity of Stellenbosch, South Africa. Mice were cared for in accordance with ethical laws on
animal manipulation. Untreated mice were killed by cervical dislocation inside the Animal
House 10 minutes after being received. Bone marrow cells were isolated from the femurs and
tibias and differentiated into macrophages as previously described [51]. Bone marrow cells
were obtained from femurs of 6–8 week-old C57BL/6 female mice and seeded into 24-well tis-
sue culture plates. The culture medium was RPMI-1640 (Sigma, USA) supplemented with 10%
heat-inactivated fetal bovine serum (Gibco), 10% L-929 cell conditioned medium (a source of
colony stimulating factor-1) with no antibiotics. Incubation was performed at 37˚C, 5% CO2.
At 5 days after seeding, adherent cells were washed twice with RPMI and re-fed with complete
medium. Medium was then renewed every second day.
Macrophage infection and harvesting of TB. Frozen aliquots of M.tb (Beijing220) were
removed from the -80˚C freezer where they were kept for long-term storage and thawed and
processed as indicated. Infection of the 7-Day old MBMM in 24-well plates was performed in
triplicates with 100 μl of bacterial suspension relative to a multiplicity of infection (MOI) of 2,
and incubated for 4 hrs at 37˚C, 5% CO2. After the 4 hr incubation period, non-ingested M.tb
(Beijing220) was removed by washing 4 times with ice-cold PBS. Fresh RPMI medium (1 ml)
was added and again on day 2. At day 4 post infection the test compounds were added at the
desired concentrations between 10 μM and 100 μM. Included were uninfected, infected (no
drug) and an isoniazid drug controls. On day 2 post drug intervention the macrophages were
washed 3 times with cold PBS (4˚C) and then the bacteria harvested by adding 1 ml 0.025%
SDS for 5 min to lyse the adherent macrophages. The contents of each well were placed into sep-
arate Eppendorf tubes and the bacteria were pelleted at 13000 rpm for 5 min. The bacteria was
resuspended in 100 μl 7H9 Middlebrook medium and then inoculated into BACTEC 460TB™
vials. Growth was monitored over time until the BACTEC 460TB™ readings of the infected (no
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drug) control reached about 500. The percentage growth inhibition for each drug compound
was determined by relating the linear growth unit readings to the infected (no drug) control.
Results
Production and purification of adenylylated and deadenylylated MtbGS
Expression strain E. coli YMC11E was constructed by deleting the chromosomal glnE gene in
the GS auxotroph YMC11. For induction of M. tuberculosis ATase expression from pTBGlnE,
the strain was lysogenised with λDE3 to create YMC11E(DE3).
Deadenylylated MtbGS was expressed from pTBSK in E. coli YMC11E. Adenylylated
MtbGS was produced in YMC11E(DE3) via co-expression of MtbGS in pTBSK and M. tuber-
culosis ATase in pTBGlnE. MtbGS was expressed constitutively, while ATase production was
induced by the addition of IPTG. The two plasmids used contain compatible origins of replica-
tion and can thus be maintained stably in the same strain. Fig 1 illustrates a SDS-PAGE of the
cell-free E. coli soluble extracts, as well as the purified adenylylated and deadenylylated forms
of MtbGS. The average protein concentrations from three purifications of adenylylated and
deadenylylated MtbGS are 120 ± 28 and 145 ± 49 μg.ml-1, respectively. The estimated size is in
agreement with the theoretical ~53.4 kDa per subunit of the MtbGS dodecamer.
Determination of the adenylylation state of adenylylated and
deadenylylated MtbGS
MS analysis of deadenylylated MtbGS, yielded a single peak with a calculated mass of
53,438.00 Da (Fig 2), in agreement with the theoretical mass of 53.4 kDa. Deadenylylated E.
coli GS had a calculated mass of 51,773.00 Da (theoretical mass = 51.7 kDa). Adenylylated E.
coli GS was calculated to be 52,102.00 Da (theoretical mass = 52.1 kDa), with a single peak
indicating 100% adenylylation. The 330 Da adenyl moiety accounts for the mass difference
between the adenylylated and deadenylylated forms of each enzyme. Adenylylated MtbGS
would not ionise properly, therefore the spectra obtained (Fig 2) that shows 85% adenylylation,
could therefore be potentially higher than 85%. In order to confirm adenylylation of MtbGS,
other methods were also pursued.
The hydrolysis of GS for determination of phosphate content was carried out on the puri-
fied enzymes to confirm the degree of adenylylation (Fig 3). Each adenyl moiety contains 1
phosphate, and 1 μM of GS (containing 12 subunits) should contain 12 μM of phosphate, if
each subunit is adenylylated. The result obtained for the adenylylated MtbGS enzyme was the
formation of 0.93 μM phosphate produced per μM GS active site, i.e. 93% adenylylated. In the
case of the deadenylylated enzyme there was no formation of phosphate. The results obtained
for E. coli GS were 0.95 μM and 0 μM for adenylylated and deadenylylated GS, respectively.
The γ-glutamyl transferase enzyme assay was carried out with purified GS to: i) confirm the
functionality of the purified MtbGS enzymes, and ii) assess the degree of adenylylation of the
purified enzyme. At a specific pH, the total enzyme activity of GS (both adenylylated and dead-
enylylated) occurs in the presence of Mn2+. At the same pH in the presence of Mn2+ and an
excess Mg2+, only the deadenylylated component of the enzyme activity is measured. The
resultant ratio is then used to calculate the degree of adenylylation of the enzyme. After three
purifications, the typical degree of adenylylation for deadenylylated MtbGS is 3 ± 2%, while
the adenylylated form is 68 ± 4% adenylylated. For comparison purposes, adenylylated and
deadenylylated E. coli GS yielded results of 0% and 87 ± 3% adenylylation, respectively.
A summary of the adenylylation state of the M. tuberculosis GS and E. coli GS as determined
by the different analysis techniques is out lined in Table 1.
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Fig 1. 12% SDS-PAGE gel of cell-free E. coli extracts, as well as purified adenylylated and deadenylylated
MtbGS. Lane 1: molecular weight marker with size in kDa indicated on left. Lane 2: Adenylylated MtbGS cell-free
extract. Lane 3: Adenylylated MtbGS purified protein. Lane 4: Deadenylylated MtbGS cell-free extract. Lane 5:
Deadenylylated MtbGS purified protein.
https://doi.org/10.1371/journal.pone.0185068.g001
Fig 2. Mass spectra of M. tuberculosis and E. coli GS purified proteins. The calculated mass and
presence of the major peak is shown within each spectrum (A) deadenylylated E. coli GS, (B) adenylylated E.
coli GS, (C) deadenylylated M. tuberculosis GS, (D) adenylylated M. tuberculosis GS.
https://doi.org/10.1371/journal.pone.0185068.g002
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Fig 3. Hydrolysis of M. tuberculosis and E. coli GS purified protein (adenylylated and deadenylylated) for phosphate concentration
determination. A blue colour indicates the presence of free phosphate.
https://doi.org/10.1371/journal.pone.0185068.g003
Table 1. Summary of the adenylylation states of M. tuberculosis and E. coli GS determined by different methods. (1) mass spectroscopy, (2) hydroly-
sis and phosphate concentration determination and (3) γ-glutamyl transferase assay.
M. tuberculosis E. coli
Deadenylylated Adenylylated Deadenylylated Adenylylated
MS 0% 85% 7% 100%
Phosphate Concentration 0 μM 0.93 μM 0 μM 0.95 μM
γ-glutamyl transferase 3 ± 2% 68 ± 4% 0 87 ± 3%
https://doi.org/10.1371/journal.pone.0185068.t001
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Specific activity, inhibitor studies, dose-response assays and M.tb
BACTEC 460TB™ assays
The specific activity of the adenylylated and deadenylylated MtbGS were determined. The con-
version of ATP to ADP was measured by HPLC and the typical specific activity of adenylylated
and deadenylylated forms of M. tuberculosis GS are 0.010 and 0.015 μmol ADP/min/mg pro-
tein, respectively.
Inhibitor studies with a library of 213 ATP scaffold based inhibitors were carried out to
reflect the differential inhibition of adenylated and deadenylated MtbGS. These assays were
also performed using the pre-incubation protocol, where the inhibitors were allowed to inter-
act with either adenylated or deadenylated MtbGS before the addition of substrates sodium
glutamate and ATP. Based on the results illustrated with the deadenylylated enzyme in Fig 4A,
six candidate inhibitors (indicated by the red data points) showed promising inhibitory activi-
ties. With the adenylylated enzyme, the % enzyme activities in the presence of the individual
compounds varied widely, producing a pronounced scatter of values around the mean and
consequently a very wide confidence interval (Fig 4B) nevertheless ten inhibitors (indicated by
the red data points) showed promising inhibitory activities with one inhibitor yielding an inhi-
bition of 99%. The scatter associated with the data when using the adenylylated GS is probably
associated with inter subunit allosteric regulation of adenylylated GS [42]. Some compounds
therefore allosterically activate the enzyme.
Fixed concentration evaluation of eleven candidate inhibitors were tested on both adenylated
and deadenylated MtbGS. Based on the results indicated in Table 2 there is a clear indication of
differential inhibition between the two forms of MtbGS. One compound (5045) displayed sig-
nificant selectivity for the deadenylylated MtbGS, while seven compounds suggested specificity
for the adenylylated MtbGS and three appeared relatively non-selective. The chemical structures
of these candidate inhibitors are indicated in Fig 5.
Dose-response assays were carried out to obtain a more accurate reflection of the activity of
adenylated and deadenylated MtbGS. These assays were performed on the 2 forms of the
enzyme to derive compound IC50 (50% inhibitory concentration) values, using the standard
GS inhibitors MSO and PhosT. Dose-response assays were performed using a pre-incubation
protocol, allowing the inhibitor to interact with the enzyme before addition of substrates
sodium glutamate and ATP. Based on the results illustrated in Fig 6, IC50 values derived from
the dose-response curves suggested, firstly, that adenylylated MtbGS is more sensitive to inhi-
bition by the standard inhibitors than the deadenylylated form of the enzyme and, secondly,
that PhosT is a more potent inhibitor of the Mtb enzymes than MSO. Compounds 10057 and
10059 both gave IC50 concentrations less than 100 μM. In duplicate assays run on different
days in triplicate the IC50 concentrations obtained were 3.51 and 15.6 μM and 13.2 and
17.1 μM, for the adenylylated enzyme and deadenylylated enzyme, respectively.
M.tb BACTEC 460TB™ assays were carried out on compounds identified following the pri-
mary screening for enzymatic activity against adenylylated and deadenylylated M.tb GS. Com-
pounds identified (see Fig 5) were tested for activity against M.tb H37Rv reference strain for
antibacterial activity. Growth inhibition was calculated as a percentage of the growth index
(GI) at day 6 of incubation where the GI of 1.0% of the control culture equalled 50 GI units. Of
the compounds directed against adenylylated GS (Fig 5), compound 10057 showed 53% (+/-
12.7) growth inhibition at 100 μM and also compound 5029 gave 66% (+/- 2.8) inhibition at
100uM against H37Rv on day 6 of incubation relative to the control cultures. However, the
growth rate (ΔGI = GI at day+1 minus GI at day) in both cases continuously increased over
the period of incubation and past day 6 of incubation indicating that bacterial doubling is tak-
ing place although at a slower rate. Most the compounds (5024, 12004, 5009, 5012, 5002, and
Differential inhibition of adenylylated and deadenylylated forms of M. tuberculosis GS
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Fig 4. M. tuberculosis GS enzyme screen using the pre-incubation protocol. The residual percentage adenylated (B) and deadenylated (A) GS enzyme
activities after incubation with 10μM of the individual compounds are shown, along with horizontal lines depicting the average % enzyme activity obtained with
all compounds, as well as an indication of the confidence interval of the results, expressed as the average activity ± 3 x standard deviation (SD). Percentage
activity obtained with methionine sulfoximine (MSO) and phosphinothricin (PhosT) is shown in blue. Candidate inhibitors previously identified in the
adenylated GS screen are shown as red datapoints. Additional compounds selected for further evaluation are shown as orange datapoints.
https://doi.org/10.1371/journal.pone.0185068.g004
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5016) showed no activity against M.tb H37Rv at 100 μM final concentration. Compound 5045,
designed to be directed against the de-adenylylated GS (Fig 5) showed an inhibition of 98%
(+/- 8.8) growth of the H37Rv mycobacterial cultures.
The 8 selective compounds identified in the enzyme assays namely compounds that were
de-adenylylated selective (5, 5002, 5012, 5016, 5029, 10057, 10059) and deadenylylated selec-
tive (5045), were tested in mouse bone-marrow derived macrophages infected with a clinical
multidrug-resistant strain actively spreading in the Western Cape region of South Africa
(Johnson et. al., 2010; Leisching et. al., 2016). Only compounds 5029, 5045, 10057 and 10059
showed activity at a concentration of 100 μM (see Fig 7). The percentage killing exhibited by
compounds 5029, 5045, 10057 and 10059 were 67%, 64%, 65% and 54% respectively at
100 μM.
The most active compounds 5029, 5045 and 10057 were tested further in macrophages at
concentrations 10 μM, 50 μM and 100 μM for 2 days (Fig 8). In this experiment compound
5045 showed the best activity (73% killing) at 100 μM. The growth inhibitory effect of com-
pound 5045 correlated well with the high inhibition observed in the extracellular BACTEC
assay against M.tb H37Rv (98% inhibition at 100μM).
Discussion
M. tuberculosis GS is a potentially valuable therapeutic target for TB drug intervention. Its reg-
ulation via adenylylation of a tyrosine residue on each subunit makes it distinct from the
human form of the enzyme. Prokaryotic GS is regulated via a complex cascade that is based on
the availability of NH4
+ and glucose to the organism and the intracellular concentrations of
2-ketoglutarate and glutamine [1, 4–8]. This regulation results in the adenylylation or deade-
nylylation of the GS with a concomitant switch in the enzymes affinity from Mn2+ to Mg2+[1,
4–8, 30]. The coordination chemistry of Mn2+ to Mg2+ are significantly different enough to
change the shape of the active site of the GS as is the effect of adenylylation. No crystal
Table 2. Fixed concentration evaluation of 11 candidate inhibitors in M.tuberculosis GS enzyme assays using the pre-incubation protocol. The
percentage enzyme inhibition obtained with the compounds (10μM final concentration) in 4 separate screens is shown, along with the average inhibition for
each compound over the 4 screens and the corresponding standard deviation (SD). The colour coding of the highlighted table cells is clarified in the bottom
legend. Compounds were defined as selective for the adenylylated or deadenylylated form of the enzyme based on at least a 30% difference in inhibition.
Adenylated Mtb GS (% inhibition) Deadenylated Mtb GS (% inhibition)
Compound (10μM) Screen 1 Screen 2 Screen 3 Screen 4 AVG SD Screen 1 Screen 2 Screen 3 Screen 4 AVG SD
PhosT 100 95 97 100 98 2 100 98 100 100 100 1
MSO 100 100 96 100 99 2 100 100 99 100 100 1
5 48 33 40 29 38 8 0 0 6 0 2 3
5002 68 40 38 35 45 15 0 10 8 14 8 6
5009 37 50 50 22 40 13 57 41 44 44 47 7
5012 55 31 32 42 40 11 14 16 4 24 15 8
5016 51 43 46 30 43 9 7 19 3 13 11 7
5024 46 48 43 36 43 5 49 44 52 44 47 4
5029 79 46 56 60 60 14 5 8 7 9 7 2
5045 0 0 0 0 0 0 44 45 54 48 48 5
10057 100 99 98 100 99 1 67 62 47 58 59 9
10059 82 99 82 100 91 10 49 48 36 43 44 6
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Fig 5. Chemical structures of the 11 synthesized ATP scaffold based inhibitors which shown promising inhibition of M. tuberculosis GS enzymes.
They are divided into three distinct groups (1) non-selective (2) Deadenylylated selective and (3) Adenylylated selective.
https://doi.org/10.1371/journal.pone.0185068.g005
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structure exits for the fully adenylylated form of the enzyme [31]. A number of studies have
been undertaken targeting MtbGS as a potential therapeutic target however, in none of these
investigations was an attempt made to exploit this dichotomy that exists between adenylylated
Fig 6. Dose-response assays for MSO and PhosT standard inhibitors. Percentage GS activity was plotted
against log (compound concentration) and sigmoidal dose-response curves fitted to the data points using non-
linear regression analysis. The curves were used to derive the IC50 values for the inhibitors (displayed in the top right
legend).
https://doi.org/10.1371/journal.pone.0185068.g006
Fig 7. Intracellular survival of M.tb (Beijing220) in mouse bone-marrow derived macrophages after 4-day post-infection period followed by
intervention on D4 PI with different compounds, MOI 2:1, 4 day incubation at 37˚C, 5% CO2. Cells were sacrificed on Day 2 Post Drug Intervention. Only
Drugs 5029, 5045, 10057 and 10059 showed moderate activity. Where not shown, error bars fall within symbols.
https://doi.org/10.1371/journal.pone.0185068.g007
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and deadenylylated GS [32–38]. Previous reports of heterologous expression of MtbGS in E.
coli have shown that the endogenous ATase activity of E. coli does not adenylylate MtbGS suffi-
ciently, with only 25% of the MtbGS subunits produced displaying adenylylation [39]. The use
of this expression system was therefore not considered optimal for the expression of adenyly-
lated MtbGS for further study.
Here, we have described an E. coli production system, lacking endogenous GS and ATase
activity, which utilises the co-expression of the M. tuberculosis ATase with MtbGS. Each gene
was provided on a separate plasmid, the glnA gene on a pBluescript SKII+ plasmid with the
ColE1 origin of replication, and the glnE gene on a pCDFDuet-1 plasmid containing a CloDF13
Fig 8. Intracellular survival of M.tb (Beijing220) in mouse bone-marrow derived macrophages after 4-day post-infection period followed by
intervention on D4 PI with different compounds, MOI 2:1, 4 day incubation at 37˚C, 5% CO2. Cells were sacrificed on Day 2 Post Drug Intervention.
Drug 5045 showed the best activity (73% killing) at 100 μM. Where not shown, error bars fall within symbols.
https://doi.org/10.1371/journal.pone.0185068.g008
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replicon. These replicons are compatible, and the two plasmids can be stably co-maintained, pro-
vided the relevant antibiotic selective pressure is exerted: ampicillin for pBluescript SKII+ and
streptomycin for pCDFDuet-1[40]. In this way, we have produced MtbGS that has a better ade-
nylylation state than any previously reported. Three methods were used to assess the adenylyla-
tion of MtbGS, and E. coli adenylylated and deadenylylated GS. The E. coli enzymes were
produced recombinantly from pBluescript SKII+ in E. coli production strains lacking endoge-
nous GS (for deadenylylated enzyme) or both GS and uridylyl transferase (adenylylated enzyme).
Table 1 gives a summary of the results obtained. MS spectra showed distinct peaks for adenyly-
lated and deadenylylated enzymes, with calculated masses agreeing with the theoretical values.
Based on this data, it can be concluded that the adenylylation state of adenylylated MtbGS
expressed in this novel system is at least 85% based on the MS data, but possibly up to 93% based
on phosphate hydrolysis. Based on this data this investigation was carried out to demonstrate the
proof-of-concept that compounds could be obtained that selectively inhibit either adenylylated
or deadenylylated MtbGS an that these compounds would inhibit Mtb in macrophages.
The fixed concentration inhibition assays of the 213 ATP based scaffold inhibitors pro-
duced 11 potential inhibitors. The scatter associated with the data when using the adenylylated
GS is probably associated with inter subunit allosteric regulation of adenylylated GS [42].
Some compounds therefore allosterically activate the enzyme. This would be achieved as a
result of allosteric regulation occurring between two GS subunits as a result of the adenylyla-
tion. It is therefore conceivable that inhibitors binding one GS subunit may either activate or
inhibit the binding of another inhibitor or ATP to the associated allosteric site. There was also
differential inhibition of the adenylylated and deadenylylated MtbGS. Seven of the potential
inhibitors were directed against adenylylated MtbGS and one was directed against deadenyly-
lated MtbGS. Two of the inhibitors namely 10057 and 10059 showed promising anti-MtbGS
activity against adenylylated MtbGS with 99% and 91% inhibition respectively. The IC50 con-
centrations obtained for compounds 10057 and 10059 were approximately 9.6 μM and 15 μM,
for the adenylylated enzyme and deadenylylated enzyme, respectively. Taking into account the
large variation in ATP and glutamine concentrations used in the screening assays similar
low μM IC50 concentrations were obtained in the enzyme screens [32–38]. Imidazopyridine
amides have been found to inhibit Mtb in other studies indicating an alternative mechanism
via the cytochrome cytochrome bc1 complex impacting on the homeostasis of ATP synthesis
[39]. The inhibition of glutamine synthetase may also impact the ATP homeostasis as the
resultant accumulation of α-ketoglutarate, as a result of inhibiting glutamine synthetase, may
lead to the slowing down of metabolic flux via the TCA cycle.
Compounds 10057 and 10059 are structurally very similar. Also in the macrophage assays
compounds 10057, 10059 and 5029 which were GS-adenylylated specific, showed comparable
activities in the BACTEC assays. This indicates that these compounds can inhibit M.tb as effec-
tively in a macrophage environment. However, compound 5045, specific to the de-adenyly-
lated form of GS, inhibited M.tb killing in both the in vitro and ex vivo macrophage models
effectively at 98% and 73% respectively at 100μM. The GS adenylylation/deadenylylation status
of the M.tb strains used in the BACTEC assay and the macrophage assays were not known
which may explain the high killing effect of both the adenylylation- and de-adenylylation spe-
cific compounds. In further development, attention may be paid to improving the selectivity
of the compounds vis-à-vismammalian forms of GS, to reduce the possibility of side-effects.
Supporting information
S1 File. Preparation of adenylylated and deadenylylated E. coli GS.
(DOCX)
Differential inhibition of adenylylated and deadenylylated forms of M. tuberculosis GS
PLOS ONE | https://doi.org/10.1371/journal.pone.0185068 October 3, 2017 19 / 22
Author Contributions
Conceptualization: I. Wiid, C. P. Kenyon.
Data curation: A. Theron, R. L. Roth, H. Hoppe, C. Parkinson, C. W. van der Westhuyzen, S.
Stoychev, I. Wiid, R. D. Pietersen, B. Baker, C. P. Kenyon.
Formal analysis: H. Hoppe, C. Parkinson, C. W. van der Westhuyzen, S. Stoychev, R. D. Pie-
tersen, B. Baker.
Funding acquisition: C. P. Kenyon.
Investigation: A. Theron, R. L. Roth, H. Hoppe, C. Parkinson, C. W. van der Westhuyzen, C.
P. Kenyon.
Methodology: C. P. Kenyon.
Supervision: R. L. Roth, C. Parkinson, C. P. Kenyon.
Validation: C. W. van der Westhuyzen, B. Baker.
Writing – original draft: A. Theron, R. L. Roth, C. W. van der Westhuyzen, I. Wiid, B. Baker,
C. P. Kenyon.
Writing – review & editing: C. W. van der Westhuyzen, I. Wiid, B. Baker, C. P. Kenyon.
References
1. Shapiro BM, Stadman ER. The regulation of glutamine synthesis in microorganisms. Ann Rev Microbiol.
1970; 24: 501–524.
2. Kumada Y, Benson DR, Hillemann TJ, Hosted DA, Rochefort CJ, Thompson W, et al. Evolution of the
glutamine synthetase gene, one of the oldest existing and functioning genes. Proc Natl Acad Sci USA.
1993; 90: 3009–3013. PMID: 8096645
3. Brown JR, Masuchi Y, Robb FT, Doolittle WF. Evolutionary relationships of bacterial and archaeal gluta-
mine synthetase genes. J Mol Evol. 1994; 38: 566–576. PMID: 7916055
4. Tyler B. Regulation of the assimilation of nitrogen compounds. Ann Rev Biochem. 1978; 47: 1127–
1162. https://doi.org/10.1146/annurev.bi.47.070178.005403 PMID: 28074
5. Gaillardin CM, Magasanik B. Involvement of the product of the glnF gene in the autogenous regulation
of glutamine synthetase formation in Klebsiella aerogenes. J Bacteriol. 1978; 133: 1329–1338. PMID:
25264
6. Foor F, Janssen KA, Magasanik B. Regulation of synthesis of glutamine synthetase by adenylylated
glutamine synthetase. Proc Natl Acad Sci USA. 1975; 72: 4844–4848. PMID: 1744
7. Janssen KA, Magasanik B. Glutamine synthetase of Klebsiella aerogenes: genetic and physiological
properties of mutants in the adenylylation system. J Bacteriol. 1977; 129: 993–1000. PMID: 14117
8. Senior PJ. Regulation of nitrogen metabolism in Escherichia coli and Klebsiella aerogenes: studies with
the continuous-culture technique. J Bacteriol. 1975; 123: 407–418. PMID: 238954
9. Ginsberg A, Stadtman ER. Regulation of glutamine synthetase in Escherichia coli. In: Prusiner SR,
Stadman ER, editors. Enzymes of Glutamine Metabolism, Academic Press, New York, 1973; p. 9–44.
10. Wolhueter RM, Schutt H, Holzer H. Regulation of glutamine synthetase in vivo in E. coli. In: Prusiner
SR, Stadman ER, editors. Enzymes of Glutamine Metabolism, Academic Press, New York, 1973; p.
45–61.
11. Bender RA, Janssen KA Resnick AD, Blumenberg M, Foor F, Magasanik B. Biochemical parameters of
glutamine synthetase from Klebsiella aerogenes. J Bacteriol. 1977; 129: 1001–1009. PMID: 14104
12. Bloom FR, Streicher SL, Tyler B. Regulation of enzyme synthesis by glutamine synthetase of Salmo-
nella typhimurium: a factor in addition to glutamine synthetase is required for activation of enzyme for-
mation. J Bacteriol. 1977; 130: 983–990. PMID: 16868
13. Holzer H, Schutt H, Masˇek Z, Mecke D. Regulation of two forms of glutamine synthetase in Escherichia
coli by the ammonium content of the growth medium. Proc Natl Acad Sci USA. 1968; 60: 721–724.
PMID: 4885513
Differential inhibition of adenylylated and deadenylylated forms of M. tuberculosis GS
PLOS ONE | https://doi.org/10.1371/journal.pone.0185068 October 3, 2017 20 / 22
14. Woolfolk CA, Shapiro B, Stadtman ER. Regulation of glutamine synthetase I. Purification and properties
of glutamine synthetase from Escherichia coli. Arch Biochem Biophys. 1966; 116: 177–192. PMID:
5336023
15. Kustu SG, McKereghan K. Mutations affecting glutamine synthetase activity in Salmonella typhimurium.
J Bacteriol. 1975; 122: 1006–1016. PMID: 238935
16. Shapiro BM, Kingdon HS, Stadtman ER. Regulation of glutamine synthetase. VII. Adenylyl glutamine
synthetase: a new form of the enzyme with altered regulatory and kinetic properties. Proc Natl Acad Sci
USA. 1967; 58: 642–649. PMID: 4860756
17. Shapiro BM, Stadtman ER. 5’-adenylyl-O-tyrosine. The novel phosphodiester residue of adenylylated
glutamine synthetase from Escherichia coli. J Bio. Chem. 1968; 243: 3769–3771.
18. Kingdon HS, Shapiro BM, Stadtman ER. Regulation of glutamine synthetase. VIII. ATP: glutamine syn-
thetase adenylyltransferase, an enzyme that catalyzes alterations in the regulatory properties of gluta-
mine synthetase. Proc Natl Acad Sci USA. 1967; 58: 1703–1710. PMID: 4867671
19. Mecke D, Wulff K, Liess K, Holzer H. Characterization of a glutamine synthetase inactivating enzyme
from Escherichia coli. Biochem Biophys Res Commun. 1966; 24: 452–458. PMID: 5338440
20. Reitzer LJ, Magasanik B. Ammonia assimilation and the biosynthesis of glutamine, glutamate, aspar-
tate, asparagine, L-alanine, and D-alanine. In: Neidart FC, Ingarhou JLL, Low KB, Magasanik B,
Schaechter M Nunberger HE, editors. Escherichia coli and Salmonella typhimurium. Cellular and
molecular biology, American Society for Microbiology, Washington DC, 1987; p. 302–320.
21. Shapiro BM, Ginsburg A. Effects of specific divalent cations on some physical and chemical properties
of glutamine synthetase from Escherichia coli. Taut and relaxed enzyme forms. Biochemistry. 1968; 7:
2153–2167. PMID: 4873174
22. Reynaud C, Etienne G, Payron P, Lenelle MA, Daffe M. Extracellular enzyme activities potentially
involved in the pathogeniticty of Mycobacterium tuberculosis. Microbiol. 1998; 144: 577–587.
23. Harth G, Horwitz MA. An inhibitor of exported Mycobacterium tuberculosis glutamine synthetase selec-
tively blocks the growth of pathogenic mycobacteria in axenic culture and in human monocytes: extra-
cellular proteins as potential drug targets. J Exp Med. 1999; 189: 1425–1435. PMID: 10224282
24. Harth G, Horwitz MA. Inhibition of Mycobacterium tuberculosis glutamine synthetase as a novel antio-
biotic strategy against tuberculosis: demonstration of efficacy in vivo. Infect Immune. 2003; 71: 456–
464.
25. Tullius MV, Harth G, Horwitz MA. Glutamine synthetase GlnA1 is essential for growth of Mycobacterium
tuberculosis in human THP-1 macrophages and guinea pigs. Infect Immun. 2003; 71: 3927–3936.
https://doi.org/10.1128/IAI.71.7.3927-3936.2003 PMID: 12819079
26. Wietzerbin J, Lederer F, Petit JF. Structural study of the poly-L-glutamic acid of the cell wall of Mycobac-
terium tuberculosis var hominis, strain Brevannes. Biochem Biophys Res Commun. 1975; 62: 246–252.
PMID: 803372
27. Hirschfield GR, McNeil M, Brennan PJ. Peptidoglycan-associated polypeptides of Mycobacterium
tuberculosis. J Bacteriol. 1990; 172: 1005–1013. PMID: 2105289
28. Harth G, Horwitz MA. Expression and efficient transport of enzymatically active Mycobacterium tuber-
culosis glutamine synthetase in Mycobacterium smegmatis and evidence that information for export is
contained within the protein. J Biol Chem. 1997; 272: 22728–22735. PMID: 9278431
29. Singh J, Joshi C, Bhatnagar R. Cloning and expression of mycobacterial glutamine synthetase gene in
Escherichia coli. Biochem Biophys Res Comun. 2004; 317:634–638.
30. Mehta R, Pearson JT, Mahajan S, Nath A, Hickey MJ, Sherman DR, et al. Adenylylation and catalytic
properties of Mycobacterium tuberculosis glutamine synthetase expressed in Escherichia coli versus
Mycobacteria. J Biol Chem. 2004: 279: 22477–22482. https://doi.org/10.1074/jbc.M401652200 PMID:
15037612
31. (2017.07.24) http://www.rcsb.org/pdb/home/home.do
32. Lagerlund O, Odell LR, Mowbray SL, Nilsson MT, Krajewski WW, Nordqvist A, et al. Microwave-
enhanced alpha-acrylation of a protected glycine in water: evaluationof 3-phenylglycine derivatives as
inhibitors of the tuberculosis enzyme, glutamine synthetase. Comb Chem High Throughput Screen.
2007; 10: 783–789. PMID: 18478959
33. Nilsson MT, Krajewski W, Yellagunda S, Prabhumurthy S, Chamarahally GN, Siddanadappa C, et al.
Structural basis for the inhibition of Mycobacterium tuberculosis glutamine synthetase by novel ATP-
competitive inhibitors. J Mol Biol. 2009; 393: 503–513.
34. Odell LR, Nilsson MT, Gising J, Lagerhund O, Muthas D, Nordqvist A, et al. Functionalized 3-amino-
imidazole[1,2a]pyridines: A novel class of drug-like Mycobacterium tuberculosis glutamine synthetase
inhibitors. Bioorg Med Chem Lett. 2009; 19: 4790–4793. https://doi.org/10.1016/j.bmcl.2009.06.045
PMID: 19560924
Differential inhibition of adenylylated and deadenylylated forms of M. tuberculosis GS
PLOS ONE | https://doi.org/10.1371/journal.pone.0185068 October 3, 2017 21 / 22
35. Gising J, Nilsson MT, Odell LR, Yahiaoui S, Lindh M, Iyer H, et al. Trisubstituted imidazoles as Myco-
bacterium tuberculosis glutamine synthetase inhibitors. J Med Chem. 2012; 55: 2894–2898. https://doi.
org/10.1021/jm201212h PMID: 22369127
36. Couturier C, Silve S, Morales R, Pesseque B, Liopart S, Nair A, et al. Nanomolar inhibitors of Mycobac-
terium tuberculosis glutamine synthetase 1: Synthesis, biological evaluation and X-ray crystallographic
studies. Bioorg Med Chem Lett. 2015; 25: 1455–1459. https://doi.org/10.1016/j.bmcl.2015.02.035
PMID: 25770781
37. Mowbray SL, Kathiravan MK, Pandey AA, Odell LR. Inhibition of glutamine synthetase: A potential drug
target in Mycobacterium tuberculosis. Molecules. 2014; 19: 13161–13176. https://doi.org/10.3390/
molecules190913161 PMID: 25162957
38. Kosikowska P, Bochno M, Maceginiak K, Forlani G, Kafarski P, Berlicki L. Bisphosphonic acids as effec-
tive inhibitors of Mycobacterium tuberculosis glutamine synthetase. J Enzyme Inhib Med Chem. 2016;
31: 931–938. https://doi.org/10.3109/14756366.2015.1070846 PMID: 26235917
39. Pethe K, Bifani P, Jang J, Kang S, Park S, Ahn S, et al. Discovery of Q203, a potent clinical candidate
for the treatment of tuberculosis. Nature Medicine. 2013; 19: 1157–1162. https://doi.org/10.1038/nm.
3262 PMID: 23913123
40. Held D, Yaeger K, Novy R. New coexpression vectors for expanded compatibilities in E. coli. Innova-
tions. 2003; 18: 406.
41. Backman K Chen Y-M, Magasanik B. Physical and genetic characterization of the glnA-glnG region of
the Escherichia coli chromosome. Proc Natl Acad Sci USA. 1981; 78: 3743–3747. PMID: 6115384
42. Shapiro BM, Stadtman ER. Glutamine Synthetase (Escherichia coli). In: Hirs CHW, Timasheff SN, edi-
tors. Methods in Enzymology 130, Elsevier, 1970; p. 910–922.
43. Laemlli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
Nature. 1970; 227: 680–685. PMID: 5432063
44. Ludden PW, Burris RH. Purification and properties of nitrogenase from Rhodospirillum rubrum, and evi-
dence for phosphate, ribose and an adenine-like unit covalently bound to the iron protein. Biochem J.
1978; 175: 251–259. PMID: 104713
45. Kenyon CP, Steyn A, Roth RL, Steenkamp PA, Nkosi TC, Oldfield LC. The role of the C8 proton of ATP
in the regulation of phosphoryl transfer within kinases and synthetases. BMC Biochem. 2011; 12: 36.
https://doi.org/10.1186/1471-2091-12-36 PMID: 21749731
46. Collins L, Franzblau SG. Microplate alamar blue assay versus BACTEC 460 system for high-throughput
screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. Antimicrob
Agents Chemother. 1997; 41(5):1004–1009. PMID: 9145860
47. Johnson R, Warren RM, van der Spuy GD, Gey van Pittius NC, Theron D, Streicher EM, et al. Drug-
resistant tuberculosis epidemic in the Western Cape driven by a virulent Beijing genotype strain. Int J
Tuberc Lung Dis. 2010; 14(1):119–121. PMID: 20003705
48. Leisching G, Pietersen RD, Mpongoshe V, van Heerden C, van Helden P, Wiid I, et al. The host
response to a clinical MDR mycobacterial strain cultured in a detergent-free environment: A global tran-
scriptomics approach. PLoS One. 2016; 11(4):e0153079. https://doi.org/10.1371/journal.pone.
0153079 PMID: 27055235
49. Siddiqi SH, Heifets LB, Cynamon MH, Hooper NM, Laszlo A, Libonati JP, et al. Rapid broth macrodilu-
tion method for determination of MICs for Mycobacterium avium isolates. J Clin Microbiol. 1993; 31
(9):2332–2338. PMID: 8408551
50. George G, Mony P, Kenneth J. Comparison of the efficacies of loop-mediated isothermal amplification,
fluorescence smear microscopy and culture for the diagnosis of tuberculosis. PLoS One. 2011: 6(6):
e21007. https://doi.org/10.1371/journal.pone.0021007 PMID: 21695047
51. De Chastellier C, Lang T, Thilo L. Phagocytic processing of the macrophage endoparasite, Mycobacte-
rium avium, in comparison to phagosomes which contain Bacillus subtilis or latex beads. Eur J Cell Biol
1995; 68:167–182. PMID: 8575463
Differential inhibition of adenylylated and deadenylylated forms of M. tuberculosis GS
PLOS ONE | https://doi.org/10.1371/journal.pone.0185068 October 3, 2017 22 / 22
